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Limited autologous vascular graft availability and poor patency rates of synthetic grafts for bypass or replacement
of small-diameter arteries remain a concern in the surgical community. These limitations could potentially be
improved by a tissue engineering approach. We report here our progress in the development and in vivo testing of
a stem-cell-based tissue-engineered vascular graft for arterial applications. Poly(ester urethane)urea scaffolds
(length¼ 10mm; inner diameter¼ 1.2mm) were created by thermally induced phase separation (TIPS). Com-
pound scaffolds were generated by reinforcing TIPS scaffolds with an outer electrospun layer of the same bio-
material (ES-TIPS). Both TIPS and ES-TIPS scaffolds were bulk-seeded with 10106 allogeneic, LacZ-transfected,
muscle-derived stem cells (MDSCs), and then placed in spinner flask culture for 48 h. Constructs were implanted
as interposition grafts in the abdominal aorta of rats for 8 weeks. Angiograms and histological assessment were
performed at the time of explant. Cell-seeded constructs showed a higher patency rate than the unseeded controls:
65% (ES-TIPS) and 53% (TIPS) versus 10% (acellular TIPS). TIPS scaffolds had a 50% mechanical failure rate with
aneurysmal formation, whereas no dilation was observed in the hybrid scaffolds. A smooth-muscle-like layer of
cells was observed near the luminal surface of the constructs that stained positive for smooth muscle a-actin
and calponin. LacZþ cells were shown to be engrafted in the remodeled construct. A confluent layer of von
Willebrand Factor–positive cells was observed in the lumen of MDSC-seeded constructs, whereas acellular con-
trols showed platelet and fibrin deposition. This is the first evidence that MDSCs improve patency and contribute
to the remodeling of a tissue-engineered vascular graft for arterial applications.
Introduction
According to the American Heart Association,cardiovascular disease claims almost 1 million lives ev-
ery year in the United States alone, and more than 50% of
those are caused by coronary artery disease.1 Attempts to
alleviate this disease include surgical procedures such as
coronary artery by-pass for myocardial revascularization,
peripheral by-pass of the limbs, and arteriovenous fistulae for
dialysis. Inadequate performance of synthetic grafts in small-
diameter (<5mm) vascular replacement and limited avail-
ability of autologous vessels make current alternatives sub-
optimal.2–5 The fabrication of a tissue-engineered vascular
graft (TEVG) appears to hold great promise for future treat-
ments of cardiovascular disease, where the development of
new conduits is clearly needed.6,7
Various approaches to achieve a fully functional TEVG
have been studied, including a completely cellular ap-
proach,8,9 decellularized matrices,10,11 and a combination of
cells and either natural or synthetic scaffolds.6,12 Two clinical
studies showed the successful implantation of a TEVG as total
cavopulmonary connection in pediatric patients using a bio-
degradable scaffold and bone marrow progenitor cells13 and
in end-stage renal disease patients as a graft for arteriovenous
fistula preparation.9
One approach in the fabrication of a TEVG is to incorpo-
rate some form of scaffold to provide mechanical integrity
upon implantation to the arterial circulation.14,15 Synthetic
biodegradable polymers can regulate the graft mechanical
properties, facilitate cell incorporation, and at the same time
be readily available, making them promising for vascular
tissue engineering applications.7,16
Departments of 1Surgery and 2Bioengineering, Center for Vascular Remodeling and Regeneration, McGowan Institute for Regenerative
Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
3Department of Orthopedic Surgery, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
TISSUE ENGINEERING: Part A
Volume 16, Number 4, 2010
ª Mary Ann Liebert, Inc.
DOI: 10.1089=ten.tea.2009.0427
1215
Most TEVGapproaches have relied onone typeof cell source
to achieve the desired biological function. Although many
previous approaches have prompted the use of terminally dif-
ferentiated smooth muscle and=or endothelial cells, these have
often shown an inability to reconstitute tissues.17Multipotential
progenitor cells that have been identified in adult tissues have
shownpromise to overcome these limitations.18–24 Efficient and
rapid incorporation of cells inside the scaffolds can also be an
important determinant for the feasibility of constructing a
clinically viable TEVG.25 We have recently reported a vacuum
seedingmethod to incorporate a large number of cells in a short
period of time with an even distribution throughout the length
and thickness of porous tubular scaffolds.26
In this study, we evaluate the in vivo remodeling of a po-
rous biodegradable elastomeric scaffold seeded with muscle-
derived stem cells (MDSCs) in a rat model after 8 weeks.
The constructs were shown to be mechanically suitable to
the systemic circulation, incorporated cells participated in the
remodeling, and patency rateswere improved comparedwith
acellular grafts. These findings might contribute to successful
clinical translation of a TEVG to treat cardiovascular disease.
Materials and Methods
Cell source
Lewis rat MDSCs were isolated by means of an established
preplating technique, and transfected with the LacZ reporter
gene as previously described.22,27 Cellswere thenplated at low
density (200 cells=cm2) on a 175 cm2 tissue culture polystyrene
flask and cultured at 378C and 5% CO2 with complete Dul-
becco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (Atlanta Biologicals, Norcross, GA), 10%
horse serum (Invitrogen, Carlsbad, CA), 100U=mL penicillin,
and 100mg=mL streptomycin. The cells were expanded to the
desired number and were used between passages 10 and 15.
Medium changes were performed every 48h during culture.
Before use, MDSC monolayers were washed three times in
Dulbecco’s modified phosphate-buffered saline (PBS) and
then incubated with 0.1% trypsin for 5min to remove them
from the flasks.MDSCswere centrifuged at 1200 rpm for 5min
to form a pellet, and then resuspended inDMEM to the desired
concentration in preparation for seeding.
Polymer synthesis
Poly(ester urethane)urea (PEUU) based on polycaprolac-
tone diol (molecular weight¼ 2000), 1,4-diisocyanatobutane
(BDI; Fluka, Milwaukee,WI), and putrescine was synthesized
as described previously using a two-step solution polymeri-
zation.16 PEUU tubular scaffolds were fabricated by com-
bining two previously described methods.28 Constructs were
formed via thermally induced phase separation (TIPS) within
a tubular mold consisting of an outer glass tube (inner di-
ameter 1.5mm) and a solid inner polytetrafluoroethylene
cylinder (outer diameter 1.3mm). Bilayered constructs were
prepared by electrospinning an outer layer of PEUU on the
surface of the TIPS constructs (ES-TIPS).29 Construct length
was approximately 15mm.
Cell seeding
To incorporate theMDSCswithin the scaffold, a previously
described rotational vacuum seeding device was utilized.26
The constructs weremounted inside the chamber between the
two tees and simultaneously perfused with 5mL of cell sus-
pension (2106 cells=mL) by means of a precision syringe
pump at a constant rate of 5mL=min. The constructs were
then flushed with 5mL of plain DMEM to wash residual cells
from the lumen of the scaffolds. The constructs were then
removed and incubated in a Petri dish for 1 h. After seeding,
the TEVGs were placed in 500mL spinner flasks (196580575;
Bellco Glass, Vineland, NJ) with 100mL of culture media and
stirred at 15 rpm for 48 h.
In vivo study design
A total of 42 adult Lewis rats (weight*300 g)were divided
in three groups and received an aortic interposition by-pass
graft. The first group (n¼ 15) received a TIPS PEUU construct
seeded with MDSCs. The second group (n¼ 17) received an
ES-TIPS PEUU construct seeded with MDSCs, whereas the
third group (n¼ 10) served as an acellular TIPS PEUU control.
Animals were electively sacrificed at 8 weeks or euthanized
earlier if ambulatory impairment or distress was evident due
to construct occlusion.
Surgical procedure
Rats were anesthetized with isofluorane (2% for induction
and 1% for maintenance) and a single dose of 5mg=100 g
ketamine intramuscular (IM), and placed on a warming pad
(378C) in the supine position.
The skin of the ventral abdomen was aseptically prepped
with povidone–iodine solution. All animal procedures were
performed in compliance with the 1996 ‘‘Guide for The Care
and Use of Laboratory Animals.’’ Briefly, a midline laparotomy
incision was made and the abdominal aorta exposed below the
renal arteries. About 40 IU of sodium heparin was given in-
travenous (IV) through a tributary vein to the inferior vena
cava. Microclamps were applied to the infrarenal aorta, proxi-
mally and distally, and the vessel was sectioned between the
clamps creating a gap of approximately 1 cm. TheTEVGgraft to
be implantedwas trimmed on both edges to obtain a 1-cm-long
construct and then sutured in place to the native aorta under
10magnification in an end-to-end interrupted anastomotic
pattern with 10.0 prolene. An average of six stitches per anas-
tomosis were utilized. After the graft was anastomosed, the
clamps were released and patency was verified by direct ob-
servation. Clamping time was approximately 25min. Finally,
the muscle layer and skin were closed with 3-0 polyglactin
absorbable suture (Vicryl; Ethicon, Boston, MA). The rats were
observed in the surgical suite until fully recovered from anes-
thesia and then returned to the housing area. The first 3 days
after surgery, buprenorphine (0.5mg=kg b.i.d.) and cefuroxime
(100mg=kg b.i.d.) were administered subcutaneously. Anti-
aggregation therapy was started after the surgery with aspirin
and dypiridamole (200mg PO daily during the first week and
100mg PO daily after the first week until sacrifice).
Angiography and gross morphology evaluation
After 8 weeks, animals were heparinized (40 IU) and
subsequently euthanized with a lethal intracardiac injection
of KCl (5mL). After death, an 18-gauge ABOcath was placed
in the thoracic descending aorta and secured with a 2.0 silk
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Dynamic angiography was performed by injecting a contrast
agent (Renograf, Glenwood, London, United Kingdom) and
images were acquired with a fluoroscopic C-arm. Patency
rate was calculated as number of animals with positive con-
trast flow through the construct over total number of animals
within each group. Mechanical failure was considered when
obvious dilation could be observed at the time of fluoros-
copy. After angiography, constructs were dissected and ex-
planted from the animal and subsequently assessed for gross
macroscopic remodeling, abscess formation, presence of in-
traluminal thrombus, and vessel wall thickening.
Microscopic evaluation
Before implantation, the trimmed edges of each construct
were fixed in paraformaldehyde and 10 mm cryosections
were incubated with Alexa 488–conjugated phalloidin (di-
lution 1:250; Sigma-Aldrich, St. Louis, MO) as previously
described to assess seeding efficacy.30
For histological assessment of explanted constructs, sepa-
rate ring segments were embedded in paraffin blocks and
5 mm sections were cut using a microtome (Thermo Shandon,
Pittsburgh, PA). Sections were mounted on slides, stained
with Masson’s trichrome and hematoxylin and eosin, and
viewed under bright light optics using a Nikon Eclipse E600
microscope.
Phenotypic assessment of newly formed tissuewas assessed
via immunofluorescence using a previously described proto-
col.30 Sections were incubated for 60min at room temperature
with the monoclonal antibodies for the following antigens:
smooth muscle alpha-actin (1:500; Sigma-Aldrich), Calponin
(1:200; Sigma-Aldrich), myosin heavy chain (1:500; Sigma-
Aldrich), and vonWillebrand Factor (1:100; Dako, Carpinteria,
CA). Unbound primary antibodywas removed by subsequent
washes in PBS. Next, the samples were incubated with a Cy3-
conjugated secondary antibody (1:500; Sigma-Aldrich) for 1 h
at room temperature and then rinsed three times for 15min
with PBS. For nuclear observation, cells were counter-stained
with 40,6-diamidino-2-phenylindole (DAPI). The sampleswere
then mounted in gelvatol and viewed under fluorescent mi-
croscopy using an Olympus Fluoview 1000 microscope.
Cell tracking was done by transducing MDSCs with a
retrovirus containing a nuclear LacZ reporter gene (a gift from
Dr. Paul Robbins, University of Pittsburgh) for 24 h and fol-
lowing the fate of the transduced cells after engraftment using
B-gal substrate (x-gal). The staining was performed on 5 mm
frozen sections fixed in 2% glutaraldehyde, followed by PBS
rinse 2, and subsequent incubation with x-gal solution at
378C overnight according to previously described protocols.
Slides were stained with eosin to facilitate imaging of LacZþ
nuclei, which stained blue.22,31
FIG. 1. In vivo implantation of a TEVG. TIPS (A) and ES-TIPS (B) preimplant sections showing MDSCs populating the
scaffolds throughout the entire thickness. (C) Schematic of surgical procedure. The TEVG is implanted in the abdominal aorta
of the rat. (D) TEVG after implant sutured to the native aorta with 10.0 prolene. TEVG, tissue-engineered vascular graft; TIPS,
thermally induced phase separation; ES-TIPS, bilayered constructs prepared by electrospinning an outer layer of poly(ester
urethane)urea on the surface of the TIPS constructs; MDSCs, muscle-derived stem cells. Color images available online at
www.liebertonline.com=ten.
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Scanning electron microscopy
Explanted constructs were fixed in 2.5% glutaraldehyde,
dehydrated in a graded series of ethanol=water solutions,
dried, and then sputter coated with gold. The surface of the
constructs was examined under a scanning electron micro-
scope operated at 3 kV.
Statistical analysis
Fisher’s exact test for nonparametric variables was used to
compare patency rates between groups. p-Values< 0.05 were
considered significant.
Results
After 48 h of dynamic culture, the constructs in group one
and two appeared completely populated with cells that were
spread inside the scaffolds (Fig. 1A, B). Surgical implantation
was feasible in all cases and no differences were noted be-
tween the groups in the surgical features of the constructs (i.e.,
tissue handling and suturability) (Fig. 1C, D). All animals
recovered well from the surgery and showed no immediate
signs of postoperative distress. In group one (TIPS-PEUU),
two animals developed signs of lower limb impairment, ab-
sence of pulses, and foot necrosis within the first 72 h that
required early sacrifice. One animal had a fatal aneurysmal
rupture at day 4. In group 2 (ES-TIPS PEUU), three animals
were sacrificed before the planned time due to ischemia on the
lower limbs but no aneurysmal failures were detected. In
group 3 (acellular TIPS-PEUU), five animals showed evidence
of lower limb ischemia that required early sacrifice within the
first week. Four animals (two in group 1 and two in group 2)
that had a self-limited necrotic plaque in the distal part of
the tail but had positive femoral pulses were treated with a
partial resection of the tail and sacrificed at the same time
as the others. All remaining animals in the three groups had a
successful clinical outcome and were electively sacrificed at
8 weeks.
Angiographic findings
The angiograms performed to evaluate patency rate (Fig.
2A–C) showed that 8 out of 15 animals (53%) in group 1 had
a patent construct with no signs of stenosis. However, four of
these animals (50%) showed aneurysmal dilation. In group 2,
11 out of 17 animals (65%) were patent with no signs of
stricture and no aneurysmswere detected. In contrast, 9 out of
10 animals in group 3 showed a clear obstruction proximal to
the graft and only 1 (10%) remained patent. There were no
significant differences in patency rate between groups 1 and 2
FIG. 2. Angiographic findings and gross morphological aspect of TEVG. (A) Unseeded TEVG control shows obstruction of
the flow at the level of the graft (arrow). (B) Seeded TIPS TEVG shows aneurysmal dilation (arrow). (C) Seeded ES-TIPS
TEVG shows patent and no dilated graft after 8 weeks (arrow). (D) Intraluminal thrombus in unseeded control. Tissue-like
aspect of explants for TIPS (E) and ES-TIPS (F) TEVG, respectively. Color images available online at www.liebertonline
.com=ten.
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( p¼ 0.22), but when compared with the acellular controls in
group 3, both groups had significantly higher patency rate
( p¼ 0.03 for group 1 vs. group 3; p¼ 0.007 for group 2 vs.
group 3).
Gross morphology findings
All patent constructs in groups 1 and 2 showed tissue-like
appearance with clear remodeling of the scaffold without
signs of scar tissue at the level of the anastomoses (Fig. 2E, F).
A smooth shiny surface was noticed in the luminal side with
almost unnoticeable transition from the native aorta. Non-
patent constructs in these groups had white organized tissue
in the lumen, mainly at the anastomoses, suggestive of inti-
mal hyperplasia formation. In group 3, all constructs but one
showed a clear intraluminal thrombus formation with little
or no remodeling of the scaffold (Fig. 2D).
Scanning electron microscopy
Surface analysis of the explanted constructs showed an
endothelial-like layer on the luminal side in groups 1 and 2
(Fig. 3) with a smooth transition from the native endothelium
to the tissue-engineered graft. There were no signs of stricture
at the anastomosis level in the patent constructs. There was a
clear integration of the native vessel wall with the implanted
polymer. In group 3, the inner layer showed the surface
completely covered by deposited platelets.
Histological findings
Histological analysis of the TEVGs in groups 1 and 2
showed formation of an external capsule with aligned colla-
gen fibers (Fig. 4). It also showed an internal tissue layer with
aligned collagen fibers and cellular components characteristic
of smooth muscle exposed to the cyclical stretching caused
by the systemic circulation. There were no signs of intimal
hyperplasia in the patent constructs consistent with the an-
giographic findings. Three of the occluded constructs in group
2 had signs of intimal thickening at the anastomosis level,
whereas the remaining three had organized scar tissue inside
the lumen, suggesting chronic thrombosis. The scaffold
showed intensive remodeling on the TIPS layer in both groups
and little or no remodeling in the electrospun layer in the case
of group 2. There was evidence of giant cells’ characteristic of
foreign body response together with a population of mono-
nuclear cells inside the scaffold, suggesting an active degra-
dation process (Fig. 4B, D, F). Although not quantified, the cell
density inside the polymer appeared to be lower than the
preimplant analysis, suggesting cell migration to both luminal
and abluminal sides. In group 3, there were almost no cellular
components inside the scaffold with scarce remodeling and a
clear organized fibrin structure in the lumen characteristic of
thrombus formation (Fig. 4A, B). X-gal staining of the sections
in groups 1 and 2 showed LacZþ cells that participated in the
remodeling corroborating the presence of the implanted
MDSCs at 8 weeks (Fig. 5A, B).
FIG. 3. Scanning electron microscopy results. (A) ES-TIPS TEVG (black arrowhead) shows a smooth transition between the
aorta and the graft, with no signs of stenosis. Note the 10.0 prolene suture at the level of the anastomosis (white arrow head).
(B) Higher magnification at the anastomosis level for a TIPS TEVG. (C) Unseeded control showing platelet adhesion on the
luminal side. (D) New endothelial layer in the center of a seeded ES-TIPS TEVG.
IN VIVO ASSESSMENT OF TEVG 1219
FIG. 4. Histological findings of TEVG explants. (A) Unseeded controls show intraluminal thrombus with no remodeling of
the scaffold. (B) Higher magnification of a different section of the same scaffold as in (A). (C) TIPS TEVG showing newly
formed tissue in the inner layer with extensive cell infiltrate and degradation of the scaffold leading to aneurysmal dilation
and rupture (arrow). (D) Higher magnification of a different section of the same TIPS scaffold as in (C): giant cells and
mononuclear infiltrates are evident within the scaffold (circled area). (E) ES-TIPS scaffold at the anastomosis level showing
the transition between native aorta (arrowhead) and the TEVG. (F) Higher magnification at the center of the ES-TIPS TEVG.
Color images available online at www.liebertonline.com=ten.
FIG. 5. LacZþ staining showing engraftment of MDSCs. (A) TIPS construct. (B) ES-TIPS TEVG. Inset shows MDSCs
participating in new capillary formation. Red¼ eosin, blue¼LacZþ transfected nuclei. Arrows indicate luminal side of
sections. Color images available online at www.liebertonline.com=ten.
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Immunohistochemistry findings
The immunohistochemical analysis showed that the inner
tissue layer noted in groups 1 and 2 was positive for both
smooth-muscle a-actin and calponin, suggesting a contractile
phenotype. The lumen of the constructs also stained positive
for von Willebrand factor, indicating the presence of endo-
thelial cells (Fig. 6). Myosin heavy chain was not positive in
any of the samples (data not shown).
Discussion
We have shown in this study that the combination of two
different processing techniques of PEUU scaffolds seeded
with MDSCs and dynamically cultured for 48 h can serve as
an arterial substitute in a rat model where the cellular compo-
nent significantly improves the patency rate when compared
with the unseeded constructs. The newly remodeled tissue
consists of aligned collagen fibers, smooth muscle cells, and
an endothelial layer. The configuration of the ES-TIPS scaf-
folds consisting of an outer electrospun layer prevents an-
eurysm formation in all cases, which is essential for arterial
applications.
For cardiovascular applications a polymer must be elastic
to be amenable to mechanical conditioning. Porosity and
pore connectivity are also important to achieve successful
cellular incorporation. PEUU biodegradable scaffolds meet
all of these requirements and are currently being studied in
several tissue engineering applications.28,29,32,33 Although
most porous scaffold processing techniques greatly reduce
the mechanical properties relative to the bulk polymer,
electrospinning retains a great deal of the strength and dis-
tensibility of the bulk PEUU.29,32 In our study, the combi-
nation of two processing techniques to obtain an ES-TIPS
scaffold provides the necessary porosity for cell support and
tissue ingrowth while maintaining the mechanical properties
to withstand systemic circulation. Moreover, there was no
difference in the remodeling of the TIPS layer and the per-
formance of the grafts when comparing groups 1 and 2,
suggesting that the electrospun layer does not affect either
the cellular activity or diffusion of nutrients.
Many of the previously described cellularized approaches
for vascular tissue engineering have relied on a long-term
culture period to reach the desired cell density and mechan-
ical strength.8,34,35 We have previously shown that vacuum
cell seeding of MDSCs within PEUU scaffolds, followed by a
short-term culture period in a dynamic environment, effec-
tively provides the initial in vitro conditions to obtain a
TEVG in a clinically relevant period of time without affecting
the stem cell phenotype of the cellular component.30 In this
study, we show in vivo evidence that such an approach is a
suitable alternative to obtain an arterial substitute in a short
period of time that is mechanically sound and biologically
active in the long term.
A similar approach to ours was described by Shin’oka
and colleagues, where a copolymer of L-lactide and
e-caprolactone was used to create a TEVG that was suc-
cessfully implanted in human patients as a pulmonary artery
replacement.13,36,37 Although the constructs were implanted
in the low pressure pulmonary circulation, they have clearly
shown the relevance of a cellular component on the patency
rate and tissue remodeling and the feasibility of clinical
application of this type of approach. Further proof of clini-
cal translation of a TEVG, but for the arterial circulation,
has been described by L’Heureux et al.9 with a completely
FIG. 6. Immunohistochemistry of TEVG. Inner new tissue layer in seeded TIPS stains positive for smooth muscle a-actin (A;
green), calponin (B; red), and Von Willebrand factor (C; green). Blue¼nuclei. (D–F) Similar findings for seeded ES-TIPS.
Arrow indicates lumen. Color images available online at www.liebertonline.com=ten.
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cellularized approach without the use of a scaffold. Although
this represents a major breakthrough in the field of tissue
engineering, the length of the fabrication process is still a
limitation with this approach.
Progenitor cells show great potential for use in tissue en-
gineering applications and may circumvent many of the
shortcomings associated with other options in cell sourcing.
In a recent study by Hashi et al. bone marrow mesenchymal
stem cells have shown antithrombogenic properties when
used in vascular applications and they reduced the amount
of intimal hyperplasia formation.38 MDSCs have previously
shown the ability to retain their phenotype for more than 30
passages with normal karyotype and were able to differen-
tiate into muscle, neural, and endothelial lineages both in vivo
and in vitro.22,23 The engraftment of MDSCs in the vascular
tissue described in this study is the first evidence of the
contribution of this cell line to the performance of an arterial
substitute. Although this study shows a clear benefit of in-
corporating a cellular component in the TEVGs, further
studies are required to elucidate the specific advantages of
MDSCs to other cell lines. However, the advantages of avail-
ability and proliferation during the fabrication process
would make the MDSCs attractive when compared with
terminally differentiated cells, even if they would be found to
have similar contributions to TEVG patency rate. Although
colocalization was not an endpoint of this study, direct
comparison between histology and LacZþ images did not
show a spatial relationship between the engrafted cells and
the new tissue formation. The mechanism of action by which
the cells prevent thrombosis of the grafts remains to be elu-
cidated, but there is evidence that stem cells and endothelial
cells release a variety of growth factors (e.g., vascular en-
dothelial growth factor and Ang-1) that play an important
role in angiogenesis and vasculogenesis.39 It has been
hypothesized that stem cells contributing to formation of
vascular tissue-engineered tissues act with an autocrine=
paracrine mechanism interacting with surrounding structures
and recruiting circulating cells to remodel the TEVG.38,39
A potential limitation of this study is the amount of poly-
mer degradation observed at 8 weeks. Although the TIPS
layer appears heavily remodeled and infiltrated, the electro-
spun layer remains intact, making it difficult to evaluate when
the newly formed tissue would replace all of the polymer and
whether it would then be mechanically sound. However, we
have observed on a separate pilot study (data not shown) that
electrospun constructs can persist in vivo for more than 6
months without failing mechanically when implanted as a
vascular graft. It is estimated that, by that time, the TIPS layer
will be sufficiently remodeled and the newly formed tissue
will be strong enough to withstand systemic circulation.
However, the degradation rate needs to be optimized in fu-
ture studies.
Conclusion
We describe here the in vivo results of an arterial TEVG
fabricated with biodegradable tubular scaffolds and seeded
with MDSCs where the cellularized constructs had a signif-
icant improvement in patency rate when compared with
unseeded controls. The ES-TIPS configuration (combination
of two different processing techniques) of the scaffolds was
essential to maintain adequate mechanical properties to with-
stand systemic circulation while still allowing rapid cell
seeding and tissue remodeling. Although longer-term end-
points and large animal studies are required, this first evi-
dence of the role of MDSCs in the in vivo performance of an
arterial TEVG could be an important milestone for future
clinical translation.
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